Merck Animal Health Introduces SEQUIVITY® with Microsol Diluvac Forte® Adjuvant Prescription Vaccine for Use in Gilts and Sows
The innovative SEQUIVITY technology provides swine producers with a safe, flexible vaccine platform to tackle existing and evolving disease challenges
RAHWAY, N.J., March 20, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it has received license approval from the U.S. Department of Agriculture (USDA) for SEQUIVITY® with Microsol Diluvac Forte® (MDF) adjuvant prescription vaccine for use in gilts and sows.
The vaccine utilizes the innovative RNA Particle Technology that is part of its legacy SEQUIVITY platform combined with the power of MDF, the same trusted adjuvant used in CIRCUMVENT® and PORCILIS® Ileitis products, to create safe, flexible, and precise vaccines to fit the unique needs of specific herds. MDF enhances the immune response to the antigens and increases the duration of immunity. The SEQUIVITY vaccine prescription platform creates custom products for influenza, rotavirus, PCV3, sapovirus and more.
The SEQUIVITY technology is a revolutionary, flexible, rapid and targeted vaccine production platform incorporating immuno-precision capabilities that protect against a wide range of disease-causing viral and bacterial pathogens in swine. While traditional vaccines can take years to develop, this technology can provide a solution in a very short timeframe. By using carefully selected gene sequences, the production platform enables the targeted creation of a vaccine as needed for rapidly evolving pathogens, thereby offering a precise solution to existing and evolving disease challenges.
“Merck Animal Health continues to shape the future of animal health by introducing innovative, science-driven ways to improve swine health and performance,” said Jeremy Maurer, V.M.D., associate director of U.S. Livestock Insights and Outcomes for Merck Animal Health. “We are excited to offer a new vaccine with an adjuvant using our SEQUIVITY technology that builds on the legacy of our innovative RNA Particle vaccine platform. It’s all supported by our web-based SEQUIVITY Dashboard to help swine producers and veterinarians make data-driven decisions based on relevant insights to address herd-specific needs.”
The vaccine comes in two bottles, a frozen antigen bottle and a diluent bottle, and is mixed at the point of use. To learn more about the SEQUIVITY swine vaccine platform from Merck Animal Health, visit SEQUIVITY.com. For prescribing information, speak to your veterinarian.
About Merck Animal Health
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).